SKI II structure
|
Common Name | SKI II | ||
---|---|---|---|---|
CAS Number | 312636-16-1 | Molecular Weight | 302.779 | |
Density | 1.4±0.1 g/cm3 | Boiling Point | 507.1±60.0 °C at 760 mmHg | |
Molecular Formula | C15H11ClN2OS | Melting Point | N/A | |
MSDS | Chinese USA | Flash Point | 260.5±32.9 °C |
Use of SKI IISKI-II is a synthetic inhibitor of sphingosine kinase (SK) activity with IC50 of 78 μM for SK1 and 45 μM for SK2.IC50 value: 78/45 μM (SK1/2) [2]Target: SKin vitro: SKI II inhibits cell proliferation by suppressing the Wnt/β-catenin signaling pathway. SKI II also reduces the expression of c-Myc and cyclin D1, the downstream target genes of the Wnt signaling pathway. SKI II inhibits cell proliferation by suppressing the Wnt/β-catenin signaling pathway. SKI II promotes the degradation of β-catenin by enhancing Wnt5A. SKI II inhibits the proliferation of HepG2 cells by blocking the Wnt/β-catenin signaling pathway. [1]in vivo: SKI-II causes an irreversible inhibition of SK1 by inducing its lysosomal and/or proteasomal degradation. In the present study, SKI-II was administered 3-weekly i.p. to LDL-R-/- mice for 16 weeks at a dose previously demonstrated to reduce tumor growth in mice. Preliminary experiments revealed that a single administration of SKI-II produces a significant reduction of plasma S1P with the maximum (40%) observed 12 h after injection. [2] |
Name | 4-[[4-(4-chlorophenyl)-1,3-thiazol-2-yl]amino]phenol |
---|---|
Synonym | More Synonyms |
Description | SKI-II is a synthetic inhibitor of sphingosine kinase (SK) activity with IC50 of 78 μM for SK1 and 45 μM for SK2.IC50 value: 78/45 μM (SK1/2) [2]Target: SKin vitro: SKI II inhibits cell proliferation by suppressing the Wnt/β-catenin signaling pathway. SKI II also reduces the expression of c-Myc and cyclin D1, the downstream target genes of the Wnt signaling pathway. SKI II inhibits cell proliferation by suppressing the Wnt/β-catenin signaling pathway. SKI II promotes the degradation of β-catenin by enhancing Wnt5A. SKI II inhibits the proliferation of HepG2 cells by blocking the Wnt/β-catenin signaling pathway. [1]in vivo: SKI-II causes an irreversible inhibition of SK1 by inducing its lysosomal and/or proteasomal degradation. In the present study, SKI-II was administered 3-weekly i.p. to LDL-R-/- mice for 16 weeks at a dose previously demonstrated to reduce tumor growth in mice. Preliminary experiments revealed that a single administration of SKI-II produces a significant reduction of plasma S1P with the maximum (40%) observed 12 h after injection. [2] |
---|---|
Related Catalog | |
References |
Density | 1.4±0.1 g/cm3 |
---|---|
Boiling Point | 507.1±60.0 °C at 760 mmHg |
Molecular Formula | C15H11ClN2OS |
Molecular Weight | 302.779 |
Flash Point | 260.5±32.9 °C |
Exact Mass | 302.028076 |
PSA | 73.39000 |
LogP | 3.91 |
Appearance of Characters | white solid |
Vapour Pressure | 0.0±1.4 mmHg at 25°C |
Index of Refraction | 1.709 |
Personal Protective Equipment | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
---|---|
RIDADR | NONH for all modes of transport |
Sphingolipids are required for efficient triacylglycerol loss in conjugated linoleic Acid treated adipocytes.
PLoS ONE 10(4) , e0119005, (2015) Conjugated linoleic acid (CLA) reduces adiposity in human and mouse adipocytes. This outcome is achieved through a variety of biological responses including increased energy expenditure and fatty acid... |
|
Sphingosine-1-phosphate receptor 3 promotes leukocyte rolling by mobilizing endothelial P-selectin.
Nat. Commun. 6 , 6416, (2015) Sphingosine-1-phosphate (S1P) participates in inflammation; however, its role in leukocyte rolling is still unclear. Here we use intravital microscopy in inflamed mouse cremaster muscle venules and hu... |
|
Ginsenoside compound K inhibits angiogenesis via regulation of sphingosine kinase-1 in human umbilical vein endothelial cells.
Arch. Pharm. Res. 37(9) , 1183-92, (2014) Ginsenoside compound K (CK) is a metabolite of the protopanaxadiol-type saponins of Panax ginseng C.A. Meyer (Araliaceae), has long been used to treat against the development of cancer, inflammation, ... |
4-{[4-(4-Chlorophenyl)-1,3-thiazol-2-yl]amino}phenol |
Phenol, 4-[[4-(4-chlorophenyl)-2-thiazolyl]amino]- |
4-[[4-(4-Chlorophenyl)-2-thiazolyl]amino]phenol |
4-(4-(4-chloro-phenyl)thiazol-2-ylamino)phenol |
Kinome_2076 |
Phenol (4-[[4-(4-chlorophenyl)-2-thiazolyl]amino] |
SKI II |
SphK-I2,Sphingosine Kinase Inhibitor 2 |
UUL |